PTPI (Petros Pharmaceuticals) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


What is Petros Pharmaceuticals Long-Term Debt?

Petros Pharmaceuticals PTPI -2.15% Long-Term Debt is $0.00 Mil as of Mar. 2026.

Petros Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Petros Pharmaceuticals's annual Long-Term Debt declined from Dec. 2023 ($6.86 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Petros Pharmaceuticals  (OTCPK:PTPI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Petros Pharmaceuticals Long-Term Debt Related Terms

Petros Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals Long-Term Debt Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 8.39 6.86 0.00 0.00

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Petros Pharmaceuticals (PTPI) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Petros Pharmaceuticals' Long-Term Debt too high?
Petros Pharmaceuticals' current Long-Term Debt is $0.00 Mil.
How does Petros Pharmaceuticals' Long-Term Debt compare to STEK and KOAN?
Petros Pharmaceuticals' Long-Term Debt of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Petros Pharmaceuticals's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.